阿奇霉素治疗SARS-CoV-2住院患者的随机对照概念验证试验(DAWn-AZITHRO)
DAWn-AZITHRO是一项在比利时15个中心开展的随机、开放标签、2期概念验证试验,计划纳入284例住院COVID-19患者,按2:1随机接受阿奇霉素(首5日每日500mg)联合标准治疗或单纯标准治疗,主要结局为入院至出院或持续临床改善(WHO 7分序贯量表改善2分且持续至少3天)的时间。
要点
- 评价阿奇霉素对住院COVID-19患者的疗效与安全性。
- 主要结局为至出院或持续临床改善的时间。
- 标准治疗可包含羟氯喹,由主治医师酌情决定。
核心结论
- 该试验旨在验证阿奇霉素能否影响COVID-19疾病进程,为当前广泛但不受控的使用提供支持或予以劝阻的依据。
研究设计与样本
- 随机、开放标签、2期概念验证、多中心临床试验,计划纳入284例住院COVID-19患者,来自比利时15个中心。
- 按9例区组随机,2:1分配至阿奇霉素联合标准治疗组或单纯标准治疗组。
- 纳入标准为有症状且72小时内经PCR或典型胸部CT确诊COVID-19、无其他诊断的住院患者。
关键数值与推荐
- 治疗组在入组后首5个连续日每日一次口服阿奇霉素500mg。
- 主要结局为从入院(第0天)至出院或至持续临床改善的时间,持续临床改善定义为WHO 7分类序贯量表改善2分且持续至少3天。
临床怎么用
- 若试验显示获益,可为阿奇霉素用于COVID-19提供证据;否则应劝阻其广泛、不受控的临床使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The rapid emergence and the high disease burden of the novel coronavirus SARS-CoV-2 have created a medical need for readily available drugs that can decrease viral replication or blunt the hyperinflammatory state leading to severe COVID-19 disease. Azithromycin is a macrolide antibiotic, known for its immunomodulatory properties. It has shown antiviral effect specifically against SARS-CoV-2 in vitro and acts on cytokine signaling pathways that have been implicated in COVID-19. METHODS: DAWn-AZITHRO is a randomized, open-label, phase 2 proof-of-concept, multicenter clinical trial, evaluating the safety and efficacy of azithromycin for treating hospitalized patients with COVID-19. It is part of a series of trials testing promising interventions for COVID-19, running in parallel and grouped under the name DAWn-studies. Patients hospitalized on dedicated COVID wards are eligible for study inclusion when they are symptomatic (i.e., clinical or radiological signs) and have been diagnosed with COVID-19 within the last 72 h through PCR (nasopharyngeal swab or bronchoalveolar lavage) or chest CT scan showing typical features of COVID-19 and without alternate diagnosis. Patients are block-randomized (9 patients) with a 2:1 allocation to receive azithromycin plus standard of care versus standard of care alone. Standard of care is mostly supportive, but may comprise hydroxychloroquine, up to the treating physician's discretion and depending on local policy and national health regulations. The treatment group receives azithromycin qd 500 mg during the first 5 consecutive days after inclusion. The trial will include 284 patients and recruits from 15 centers across Belgium. The primary outcome is time from admission (day 0) to life discharge or to sustained clinical improvement, defined as an improvement of two points on the WHO 7-category ordinal scale sustained for at least 3 days. DISCUSSION: The trial investigates the urgent and still unmet global need for drugs that may impact the disease course of COVID-19. It will either provide support or else justify the discouragement of the current widespread, uncontrolled use of azithromycin in patients with COVID-19. The analogous design of other parallel trials of the DAWN consortium will amplify the chance of identifying successful treatment strategies and allow comparison of treatment effects within an identical clinical context. TRIAL REGISTRATION: EU Clinical trials register EudraCT Nb 2020-001614-38 . Registered on 22 April 2020.
引用
- Gyselinck I, Liesenborghs L, Landeloos E, et al. Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial. Trials. 2021. PMID: 33563325. doi:10.1186/s13063-021-05033-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。